Академический Документы
Профессиональный Документы
Культура Документы
On 16 December 2014
Summary
A leading business intelligence provider, has released its latest research report, "Melanoma
Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive
Market Growth
Melanoma is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular
Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according
to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of
the body. CM is by far the most common form of melanoma, accounting for approximately 90
95% of all melanomas.
Scope
The report analyzes treatment usage patterns, drug types available and pipeline and market
forecasts across indications for melanoma.The report covers and includes - An introduction to the melanoma indication, including disease symptoms, epidemiology,
etiology, pathophysiology, staging, diagnosis and treatment.
- In-depth analysis of the current melanoma marketed products landscape including product
profiles of the main drugs used in melanoma and heat maps that compare safety and efficacy
parameters of the various drugs.
- Comprehensive analysis of the melanoma pipeline by phase of development, molecule type,
molecular target and novelty. A comparative analysis of late-stage pipeline drugs that are likely
to enter the market in the forecast period is also provided alongside heat maps.
- Additional in-depth analysis of melanoma clinical trials by size, duration, failure rates and
primary and secondary endpoints.
- Multi-scenario forecast data for the market to 2020, taking into account how it will be
affected by the introduction of new drugs and changes in disease epidemiology across the key
developed markets, the US, Canada, the UK, France, Germany, Italy, Spain and Japan.
- Discussion of the licensing and co-development strategic consolidations landscape in
melanoma, by Phase of development and molecule type, as well as an analysis of both licensing
and co-development deals by year, and network maps of licensing and co-development deals.
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/
Reasons to buy
The report will assist business development and enable marketing executives to strategize their
product launches, by allowing them to
- Gain a comprehensive understanding of the melanoma indication including segmentation of
disease and treatment algorithms.
- Understand the current melanoma marketed products landscape and recognize the dominant
therapeutic agents and pharmaceutical players involved.
- Identify trends and developments within the melanoma pipeline including which molecule
types and molecular targets are prominent.
- Consider market opportunities and potential risks by examining trends in melanoma clinical
trial duration and size, as well as clinical trial failure rates, amongst clinical trial Phases and
molecule types.
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules
on the melanoma therapeutics market.
Table of Content
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 11
2.1 Disease Introduction 11
2.2 Types of Melanoma 12
2.3 Symptoms 13
2.3.1 Cutaneous Melanoma 13
2.3.2 Ocular Melanoma 14
2.3.3 Mucosal Melanomas 14
2.3.4 Melanomas of the Internal Organs and Soft Parts 14
2.3.5 Advanced Melanoma 15
2.4 Etiology and Risk Factors 15
2.4.1 Phenotypic Characteristics 15
2.4.2 Exposure to Ultraviolet Radiation 16
2.4.3 Personal or Family History of Melanoma 17
2.4.4 Xeroderma Pigmentosum 18
2.4.5 Parkinsons Disease 18
2.5 Pathophysiology 18
2.5.1 Cutaneous Melanoma 18
2.5.2 Ocular Melanoma 19
2.5.3 Mucosal Melanoma 20
2.5.4 Underlying Molecular Pathways 20
2.6 Melanoma Staging 22
2.7 Diagnosis 25
2.7.1 Cutaneous Melanoma 25
2.7.2 Ocular Melanoma 25
2.7.3 Mucosal Melanoma 26
2.8 Epidemiology 26
2.8.1 Cutaneous Melanoma 26
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/
List Of Tables
Table 7: Melanoma Therapeutics, Global, All Pipeline Products, Discovery Phase, 2014 149
Table 8: Melanoma Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 151
Table 9: Melanoma Therapeutics, Global, All Pipeline Products, IND/CTA-filed Phase, 2014 157
Table 10: Melanoma Therapeutics, Global, All Pipeline Products, Phase I, 2014 157
Table 11: Melanoma Therapeutics, Global, All Pipeline Products, Phase II, 2014 160
Table 12: Melanoma Therapeutics, Global, All Pipeline Products, Phase III, 2014 165
Table 13: Melanoma Therapeutics, Global, All Pipeline Products, Pre-registration Phase, 2014
166
Table 14: Melanoma Therapeutics Market, Global, Market Forecast, 20132020 166
Table 15: Melanoma Therapeutics Market, US, Market Forecast, 20132020 166
Table 16: Melanoma Therapeutics Market, Canada, Market Forecast, 20132020 167
Table 17: Melanoma Therapeutics Market, UK, Market Forecast, 20132020 167
Table 18: Melanoma Therapeutics Market, France, Market Forecast, 20132020 168
Table 19: Melanoma Therapeutics Market, Germany, Market Forecast, 20132020 168
Table 20: Melanoma Therapeutics Market, Italy, Market Forecast, 20132020 169
Table 21: Melanoma Therapeutics Market, Spain, Market Forecast, 20132020 169
Table 22: Melanoma Therapeutics Market, Japan, Market Forecast, 20132020 170
Table 23: List of Abbreviations 183
List Of Figures
Figure 1: Melanoma Therapeutics Market, Global, Heat Map for Adjuvant Marketed Products,
2014 65
Figure 2: Melanoma Therapeutics Market, Global, Heat Map for Advanced Marketed Products,
2014 66
Figure 3: Melanoma Therapeutics Market, Global, Heat Map for Advanced Marketed Products,
2014 (continued) 67
Figure 4: Melanoma Therapeutics Market, Global, Pipeline, 2014 71
Figure 5: Melanoma Therapeutics Market, Global, Pipeline, Breakdown of Biologics and
Gene/Cell Therapies, 2014 73
Figure 6: Melanoma Therapeutics Market, Global, Pipeline, Repositioned Molecules by Original
Indication, 2014 74
Figure 7: Melanoma Therapeutics Market, Global, Pipeline by Molecular Target, 2014 76
Figure 8: Melanoma Therapeutics Market, Global, Pipeline, Breakdown of Protein Kinase
Molecular Targets by Phase of Development, 2014 78
Figure 9: Melanoma Therapeutics Market, Global, Pipeline, Breakdown of Antigens/Antigen
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/
Figure 29: Melanoma Therapeutics Market, Global, Heat Map for Advanced Pipeline Products,
2014 (continued) 113
Figure 30: Melanoma Therapeutics Market, Global, Competitor Matrix for Advanced Products,
2014 114
Figure 31: Melanoma Therapeutics Market, Global, Treatment Patterns (000) and Market Size
($bn), 20132020 118
Figure 32: Melanoma Therapeutics Market, North America, Treatment Patterns, 20132020 122
Figure 33: Melanoma Therapeutics Market, North America, Annual Cost of Therapy ($), 2013
2020 123
Figure 34: Melanoma Therapeutics Market, North America, Market Size, 20132020 125
Figure 35: Melanoma Therapeutics Market, Five EU Countries, Treatment Patterns (000), 2013
2020 126
Figure 36: Melanoma Therapeutics Market, Top Five EU Countries, Annual Cost of Therapy ($),
20132020 128
Figure 37: Melanoma Therapeutics Market, Top Five EU Countries, Market Size ($m), 2013
2020 129
Figure 38: Melanoma Therapeutics Market, Japan, Treatment Usage Patterns (000), 20132020
130
Figure 39: Melanoma Therapeutics Market, Japan, Annual Cost of Therapy ($), 20132020 131
Figure 40: Melanoma Therapeutics Market, Japan, Market Size ($m), 20132020 132
Figure 41: Melanoma Therapeutics Market, Global, Co-development Deals by Region, 2006
2014 135
Figure 42: Melanoma Therapeutics Market, Global, Co-development Deals by Deal Value, 2006
2014 136
Figure 43: Melanoma Therapeutics Market, Global, Co-development Deals by Year, 20062014
137
Figure 44: Melanoma Therapeutics Market, Global, Co-development Deals by Phase of
Development, Deal Value and Upfront Payment ($m), 20062014 138
Figure 45: Melanoma Therapeutics Market, Co-development Deals by Phase of Development,
Molecule Type and Aggregate Deal Value ($m), 20062014 139
Figure 46: Melanoma Therapeutics Market, Global, Licensing Deals by Region, 20062014 141
Figure 47: Melanoma Therapeutics Market, Global, Licensing Deals by Deal Value, 20062014
142
Figure 48: Melanoma Therapeutics Market, Global, Licensing Deals by Year, 20062014 143
Figure 49: Melanoma Therapeutics Market, Global, Licensing Deals by Phase of Development,
Deal Value and Upfront Payment ($m), 20062014 144
Figure 50: Melanoma Therapeutics Market, Licensing Deals by Phase of Development, Molecule
Type and Aggregate Deal Value ($m), 20062014 145
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/
Report Price:
Licence Type
Price
$ 4995
Site Licence
$ 9990
$ 14985
Related Reports:
Complicated Intra-Abdominal Infections Global Clinical Trials Review, H2, 2014
Gram-Negative Bacterial Infections Global Clinical Trials Review, H2, 2014
H1N1 Infection Global Clinical Trials Review, H2, 2014
Post-Operative Pain - Pipeline Review, H2 2014
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2014
Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2014
Chemotherapy Induced Neutropenia - Pipeline Review, H2 2014
Critical Limb Ischemia - Pipeline Review, H2 2014
Thyroid Cancer - Pipeline Review, H2 2014
Fragile X Syndrome - Pipeline Review, H2 2014
You can order this report by calling on +91 - 998 7295 242 or mail us
your contact details at contact@jsbmarketresearch.com
About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along
with providing in-depth analysis though reports, JSB market research also provides regular
updates of the market though newsletters. Our reports are a well-researched work of market
researchers with an extensive knowledge and a good level of market experience.